<div id="readability-page-1">08:29 AM EST, 11/26/2025 (MT Newswires) -- BioNTech (BNTX) said Wednesday that CureVac ( CVAC ) shareholders approved matters related to BioNTech's exchange offer at an extraordinary general meeting, with 99.16% voting in favor of the proposals.The exchange ratio has been set at 0.05363 of a BioNTech American depository share for each CureVac ( CVAC ) share, based on the 10-day volume-weighted average price of BioNTech ADSs through Nov. 25, 2025, the company said.BioNTech said it expects to complete the offer as soon as practicable. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

BNTX

BioNTech 宣佈，CureVac 股東以 99.16% 的投票支持批准了交換提議。交換比例設定為每股 CureVac 股票兑換 0.05363 股 BioNTech 美國存托股票（ADS）。BioNTech 預計將很快完成該提議

BioNTech 對 CureVac 的公開交換要約已獲得股東的批准